Dallas, Texas, April 18, 2025 (Globe Newswire) – 
While Berkshire Biomedical is approaching the end of his equity crowdfunding campaign Start -upThe company will host its last investor-oriented webinar Thursday, April 24 at 13:30 pst. The session offers a deeper view of how Berkshire’s Copa ™ (automated oral prescription management) could enter into urgent challenges in safety, compliance and abuse of medicines in a wide range of therapeutic categories.
Although Berkshire’s initial market focus will be for COPA for medication for opioid user disorder (MOUD), the precision, control and real -time connectivity can have far -reaching applications. The upcoming webinar will investigate its potential use when treating chronic pain, ADHD, epilepsy, Alzheimer’s disease and supporting post-surgical recovery, with a focus on reducing risks, improving the results and engaging safe, personalized care.
John TimberlakePresident and CEO of Berkshire Biomedical, the discussion will be next Tom KingSenior adviser of the company. The speakers will also investigate the potential value of COPA for clinical research organizations and pharmaceutical partners as a digital platform for medicine output for clinical studies and risky medicines.
Participants will hear how the COPA platform could support both patients, care providers and care teams – and how their integration in clinical and commercial environments could unlock strategic partnerships, licenses and future institutional growth opportunities.
This is the last chance to participate directly with the business leadership before the Berkshire Biomedical Start Engine campaign closes.
About Berkshire Biomedical Corporation
Berkshire Biomedical Corporation is a private company for medical devices. Berkshire pioneers in the use of biometric technologies, combined with coded hipaa-conformed cloud-based and care provider-based external management systems, to offer precise and accurate personalized medicine episode to only the verified intended user (AIU).
The main product of the company in Development, the automated oral recepture management system (COPA), is a hand-automated, automated, personalized oral liquid dispensing system designed and intended to provide controlled and non-controlled oral drugs to only the Dubbing printing and aiu Nauition.
After receiving the legal permission, the company is initially planning to look for opportunities to use COPA in the delivery and external management of mouth -fluid medication Methadone, for medication use for treatment with opioid use and then for the delivery of controlled drugs for the treatment of pain, because patients need the benefits of Copa’s own property.
As previously announced, the COPA company has developed with the support of a Fast-Track Small Business Innovation Research Grant of $ 2.0 million from the National Institute On Drug ABUSE of the National Institutes of Health under Award number R4DA057185.
In the future, the company will try to extend COPA use to a broader set of drug therapeutics and possible clinical applications, as well as with companies that use data analyzes and commercialize that is provided by electronic devices to improve the results and reduce the risk.
The COPA system is currently under development, has not been rated by the US Food and Drug Administration and is not available for commercial sale.
